Corbus Pharmaceuticals (CRBP) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 14.7% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -85.1% for UNCY. Unicycive Therapeutics is the larger company by market cap ($113.8 million vs $106.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | UNCY |
|---|---|---|
| Share price | $5.50 | $4.16 |
| Market cap | $106.38M | $113.82M |
| 1-day change | +4.36% | +2.09% |
| YTD return | -35.26% | -29.46% |
| 1-year return | -60.73% | -14.68% |
| 5-year return | -82.78% | -85.06% |
| Forward P/E | — | 2.46 |
| EPS (TTM) | $-6.11 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $8.74 |
| 52-week low | $5.13 | $3.93 |
| Distance from 52-week high | -73.25% | -52.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +518.73% | +583.51% |
| Average volume | 756.54K | 839.29K |
| Shares outstanding | 19.34M | 27.39M |
| Employees | 36 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed CRBP by 46.1 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CRBP vs UNCY FAQ
Which is bigger, Corbus Pharmaceuticals or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $113.82M compared with $106.38M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or UNCY?
UNCY returned -14.68% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.